Veraxa Biotech AG Estimates – NASDAQ:VRXA

At $1.09 a share, director Ziegler buys 30,000 Veraxa Biotech (VRXA) shares.

VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline

VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Veraxa Biotech stock gains on FDA-aligned testing strategy

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

Why is Veraxa Biotech stock climbing today?

VERAXA Biotech (NASDAQ: VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress

VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

VERAXA Biotech Designates Raju Willener as CFO

Veraxa Biotech Stock: Post-Merger Valuation Does Not Match The Risk (NASDAQ:VRXA)

symbol__ Stock Quote Price and Forecast